New Drugs for Migraine

Overview

Journal J Headache Pain

Publisher Biomed Central

Date 2009 Oct 2

PMID 19795182

Citations 16

Authors

Lars Jacob Stovner

Erling Tronvik

Knut Hagen

Affiliations

Soon will be listed here.

Abstract

After the triptans, a calcitonin gene-related peptide blocker (telcagepant) is the first acute medicine that has been developed primarily for treatment of acute migraine. Otherwise, the new drugs have been developed first for other purposes, like anticonvulsants, antihypertensives and antidepressants used for migraine prophylaxis. For acute attacks, a new way to administer a traditional drug like dihydroergotamine is under way, and documentation of efficacy in migraine has been gained for some commonly used painkillers and anti-inflammatory drugs, and for some herbal extracts. Based on insights into the basic pathophysiological mechanisms of the disorder, some drugs have been developed which seem promising in early phase II studies (NOS inhibitors and 5HT1F-receptor agonists). In the future, development and enhancements of existing medicines must be accompanied by increased efforts to develop truly new migraine drugs based on knowledge of the pathophysiology if one wishes to reduce substantially the great burden migraine poses on patients and society.

Citing Articles

The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.

van Hoogstraten W, MaassenVanDenBrink A J Headache Pain. 2019; 20(1):54.

PMID: 31096904 PMC: 6734450. DOI: 10.1186/s10194-019-1007-y.

Anti-migraine effect of ∆-tetrahydrocannabinol in the female rat.

Kandasamy R, Dawson C, Craft R, Morgan M Eur J Pharmacol. 2017; 818:271-277.

PMID: 29111112 PMC: 5742305. DOI: 10.1016/j.ejphar.2017.10.054.

Neurovascular contributions to migraine: Moving beyond vasodilation.

Jacobs B, Dussor G Neuroscience. 2016; 338:130-144.

PMID: 27312704 PMC: 5083225. DOI: 10.1016/j.neuroscience.2016.06.012.

Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.

Frisk P, Sporrong S, Ljunggren G, Wettermark B, von Euler M Eur J Clin Pharmacol. 2016; 72(6):747-54.

PMID: 26922586 DOI: 10.1007/s00228-016-2028-y.

ASICs as therapeutic targets for migraine.

Dussor G Neuropharmacology. 2015; 94:64-71.

PMID: 25582295 PMC: 4458434. DOI: 10.1016/j.neuropharm.2014.12.015.

References

Silberstein S, Freitag F, Rozen T, Kudrow D, Hewitt D, Jordan D . Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial. Headache. 2005; 45(10):1317-27. DOI: 10.1111/j.1526-4610.2005.00264.x. View

Diener H, Bussone G, van Oene J, Lahaye M, Schwalen S, Goadsby P . Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27(7):814-23. DOI: 10.1111/j.1468-2982.2007.01326.x. View

Ho T, Ferrari M, Dodick D, Galet V, Kost J, Fan X . Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372(9656):2115-23. DOI: 10.1016/S0140-6736(08)61626-8. View

Mauskop A, Mathew N . Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology. 2009; 72(15):1367. DOI: 10.1212/WNL.0b013e3181a53375. View

Levy M, Matharu M, Bhola R, Meeran K, Goadsby P . Octreotide is not effective in the acute treatment of migraine. Cephalalgia. 2004; 25(1):48-55. DOI: 10.1111/j.1468-2982.2004.00807.x. View

Loo C, Tan H, Teh H, Raymond A . Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine. Singapore Med J. 2007; 48(9):834-9. View

Steiner T . Lifting The Burden: the global campaign to reduce the burden of headache worldwide. J Headache Pain. 2005; 6(5):373-7. PMC: 3452068. DOI: 10.1007/s10194-005-0241-7. View

Merkus F, Lohman J, ter Berg J, Hooymans P . Hydroxocobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open, pilot study. Cephalalgia. 2002; 22(7):513-9. DOI: 10.1046/j.1468-2982.2002.00412.x. View

Ferrari M, Goadsby P, Roon K, Lipton R . Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22(8):633-58. DOI: 10.1046/j.1468-2982.2002.00404.x. View

10.

Dahlof C . Integrating the triptans into clinical practice. Curr Opin Neurol. 2002; 15(3):317-22. DOI: 10.1097/00019052-200206000-00015. View

11.

Gupta V . Botulinum toxin--a treatment for migraine? A systematic review. Pain Med. 2006; 7(5):386-94. DOI: 10.1111/j.1526-4637.2006.00216.x. View

12.

Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L . Topiramate in the treatment of chronic migraine. Cephalalgia. 2003; 23(8):820-4. DOI: 10.1046/j.1468-2982.2003.00592.x. View

13.

DAmico D, Grazzi L, Bussone G . Topiramate in the prevention of migraine: a review of its efficacy, tolerability, and acceptability. Neuropsychiatr Dis Treat. 2009; 2(3):261-7. PMC: 2671823. DOI: 10.2147/nedt.2006.2.3.261. View

14.

Andlin-Sobocki P, Jonsson B, Wittchen H, Olesen J . Cost of disorders of the brain in Europe. Eur J Neurol. 2005; 12 Suppl 1:1-27. DOI: 10.1111/j.1468-1331.2005.01202.x. View

15.

Brighina F, Palermo A, Aloisio A, Francolini M, Giglia G, Fierro B . Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study. Clin Neuropharmacol. 2006; 29(6):338-42. DOI: 10.1097/01.WNF.0000236766.08409.03. View

16.

Diener H, Rahlfs V, Danesch U . The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol. 2004; 51(2):89-97. DOI: 10.1159/000076535. View

17.

White H . Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache. 2005; 45 Suppl 1:S48-56. DOI: 10.1111/j.1526-4610.2005.4501006.x. View

18.

Pakalnis A, Kring D, Meier L . Levetiracetam prophylaxis in pediatric migraine--an open-label study. Headache. 2007; 47(3):427-30. DOI: 10.1111/j.1526-4610.2007.00728.x. View

19.

Saavedra J, Benicky J, Zhou J . Angiotensin II: multitasking in the brain. J Hypertens Suppl. 2006; 24(1):S131-7. DOI: 10.1097/01.hjh.0000220418.09021.ee. View

20.

Tvedskov J, Lipka K, Ashina M, Iversen H, Schifter S, Olesen J . No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol. 2005; 58(4):561-8. DOI: 10.1002/ana.20605. View